Clinical trial · Interventional
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
Dose-response of Aerobic Training During Chemotherapy for Gastrointestinal Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find the level of aerobic exercise (AT) that is practical, is safe, and has positive effects on the body that may reduce the side effects of therapy. The study will also look at the way the body responds to exercise and whether there are differences in treatment. This will include looking at the highest treatment dose participants receive, how many people stop, delay, or reduce the treatment, and whether additional medication is needed to treat side effects of therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| structured treadmill walking | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- 90 min/wk
- description
- AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 1: 90 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.
- interventionNames
- Behavioral: structured treadmill walking
- type
- EXPERIMENTAL
- label
- 150 mins/wk
- description
- AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 2: 150 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.
- interventionNames
- Behavioral: structured treadmill walking
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged ≥18 years * Diagnosed with colorectal or esophago/gastric solid tumors as defined by one of the following: * Histological confirmation * As per standard of care imaging * Scheduled to receive neoadjuvant chemotherapy or chemotherapy for newly diagnosed metastatic disease * Performing ≤90 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report * Willingness to comply with all study-related procedures * Cleared for exercise participation as per screening clearance via the Physical Activity Readiness Questionnaire Exclusion Criteria: * Enrollment onto any other lifestyle interventional investigational study, except interventions determined by the PI not to confound study outcomes * Receiving treatment for any other diagnosis of invasive cancer * Mental impairment leading to inability to cooperate * Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation
References
Publications (0)
Data not yet available